Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases

David Trofa, Mariangela Agovino, Frank Stehr, Wilhelm Schäfer, Dmitry Rykunov, András Fiser, Z. Hamari, Joshua D. Nosanchuk, A. Gácser

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A reconstituted human tissue model was used to mimic Candida albicans and Candida parapsilosis infection in order to investigate the protective effects of acetylsalicylic acid (aspirin, ASA). We found that therapeutic concentrations of ASA reduced tissue damage in the in vitro infection model. We further evaluated the lipase inhibitory effects of ASA by investigating the growth of C. albicans, C. parapsilosis and C. parapsilosis lipase negative (Δcplip1-2/Δcplip1-2) mutants in a lipid rich minimal medium supplemented with olive oil and found that a therapeutic concentration of ASA inhibited the growth of wild type fungi. The lipase inhibitors quinine and ebelactone B were also shown to reduce growth and protect against tissue damage from Candida species, respectively. A lipolytic activity assay also showed that therapeutic concentrations of ASA inhibited C. antarctica and C. cylindracea purified lipases obtained through a commercial kit. The relationship between ASA and lipase was characterized through a computed structural model of the Lipase-2 protein from C. parapsilosis in complex with ASA. The results suggest that development of inhibitors of fungal lipases could result in broad-spectrum therapeutics, especially since fungal lipases are not homologous to their human analogues.

Original languageEnglish
Pages (from-to)1131-1139
Number of pages9
JournalMicrobes and Infection
Volume11
Issue number14-15
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Lipase
Candida
Aspirin
Candida albicans
Growth
Quinine
Structural Models
Therapeutics
Protein C
Infection
Fungi
Lipids

Keywords

  • Acetylsalicylic acid
  • Candida
  • Human fungal pathogen
  • Inhibition
  • Lipases
  • Pathogenesis
  • Yeast

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases. / Trofa, David; Agovino, Mariangela; Stehr, Frank; Schäfer, Wilhelm; Rykunov, Dmitry; Fiser, András; Hamari, Z.; Nosanchuk, Joshua D.; Gácser, A.

In: Microbes and Infection, Vol. 11, No. 14-15, 12.2009, p. 1131-1139.

Research output: Contribution to journalArticle

Trofa, David ; Agovino, Mariangela ; Stehr, Frank ; Schäfer, Wilhelm ; Rykunov, Dmitry ; Fiser, András ; Hamari, Z. ; Nosanchuk, Joshua D. ; Gácser, A. / Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases. In: Microbes and Infection. 2009 ; Vol. 11, No. 14-15. pp. 1131-1139.
@article{dddec5a2c24c4cfc852eb04a3dbd42e3,
title = "Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases",
abstract = "A reconstituted human tissue model was used to mimic Candida albicans and Candida parapsilosis infection in order to investigate the protective effects of acetylsalicylic acid (aspirin, ASA). We found that therapeutic concentrations of ASA reduced tissue damage in the in vitro infection model. We further evaluated the lipase inhibitory effects of ASA by investigating the growth of C. albicans, C. parapsilosis and C. parapsilosis lipase negative (Δcplip1-2/Δcplip1-2) mutants in a lipid rich minimal medium supplemented with olive oil and found that a therapeutic concentration of ASA inhibited the growth of wild type fungi. The lipase inhibitors quinine and ebelactone B were also shown to reduce growth and protect against tissue damage from Candida species, respectively. A lipolytic activity assay also showed that therapeutic concentrations of ASA inhibited C. antarctica and C. cylindracea purified lipases obtained through a commercial kit. The relationship between ASA and lipase was characterized through a computed structural model of the Lipase-2 protein from C. parapsilosis in complex with ASA. The results suggest that development of inhibitors of fungal lipases could result in broad-spectrum therapeutics, especially since fungal lipases are not homologous to their human analogues.",
keywords = "Acetylsalicylic acid, Candida, Human fungal pathogen, Inhibition, Lipases, Pathogenesis, Yeast",
author = "David Trofa and Mariangela Agovino and Frank Stehr and Wilhelm Sch{\"a}fer and Dmitry Rykunov and Andr{\'a}s Fiser and Z. Hamari and Nosanchuk, {Joshua D.} and A. G{\'a}cser",
year = "2009",
month = "12",
doi = "10.1016/j.micinf.2009.08.007",
language = "English",
volume = "11",
pages = "1131--1139",
journal = "Microbes and Infection",
issn = "1286-4579",
publisher = "Elsevier Masson SAS",
number = "14-15",

}

TY - JOUR

T1 - Acetylsalicylic acid (aspirin) reduces damage to reconstituted human tissues infected with Candida species by inhibiting extracellular fungal lipases

AU - Trofa, David

AU - Agovino, Mariangela

AU - Stehr, Frank

AU - Schäfer, Wilhelm

AU - Rykunov, Dmitry

AU - Fiser, András

AU - Hamari, Z.

AU - Nosanchuk, Joshua D.

AU - Gácser, A.

PY - 2009/12

Y1 - 2009/12

N2 - A reconstituted human tissue model was used to mimic Candida albicans and Candida parapsilosis infection in order to investigate the protective effects of acetylsalicylic acid (aspirin, ASA). We found that therapeutic concentrations of ASA reduced tissue damage in the in vitro infection model. We further evaluated the lipase inhibitory effects of ASA by investigating the growth of C. albicans, C. parapsilosis and C. parapsilosis lipase negative (Δcplip1-2/Δcplip1-2) mutants in a lipid rich minimal medium supplemented with olive oil and found that a therapeutic concentration of ASA inhibited the growth of wild type fungi. The lipase inhibitors quinine and ebelactone B were also shown to reduce growth and protect against tissue damage from Candida species, respectively. A lipolytic activity assay also showed that therapeutic concentrations of ASA inhibited C. antarctica and C. cylindracea purified lipases obtained through a commercial kit. The relationship between ASA and lipase was characterized through a computed structural model of the Lipase-2 protein from C. parapsilosis in complex with ASA. The results suggest that development of inhibitors of fungal lipases could result in broad-spectrum therapeutics, especially since fungal lipases are not homologous to their human analogues.

AB - A reconstituted human tissue model was used to mimic Candida albicans and Candida parapsilosis infection in order to investigate the protective effects of acetylsalicylic acid (aspirin, ASA). We found that therapeutic concentrations of ASA reduced tissue damage in the in vitro infection model. We further evaluated the lipase inhibitory effects of ASA by investigating the growth of C. albicans, C. parapsilosis and C. parapsilosis lipase negative (Δcplip1-2/Δcplip1-2) mutants in a lipid rich minimal medium supplemented with olive oil and found that a therapeutic concentration of ASA inhibited the growth of wild type fungi. The lipase inhibitors quinine and ebelactone B were also shown to reduce growth and protect against tissue damage from Candida species, respectively. A lipolytic activity assay also showed that therapeutic concentrations of ASA inhibited C. antarctica and C. cylindracea purified lipases obtained through a commercial kit. The relationship between ASA and lipase was characterized through a computed structural model of the Lipase-2 protein from C. parapsilosis in complex with ASA. The results suggest that development of inhibitors of fungal lipases could result in broad-spectrum therapeutics, especially since fungal lipases are not homologous to their human analogues.

KW - Acetylsalicylic acid

KW - Candida

KW - Human fungal pathogen

KW - Inhibition

KW - Lipases

KW - Pathogenesis

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=71649104743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649104743&partnerID=8YFLogxK

U2 - 10.1016/j.micinf.2009.08.007

DO - 10.1016/j.micinf.2009.08.007

M3 - Article

C2 - 19703582

AN - SCOPUS:71649104743

VL - 11

SP - 1131

EP - 1139

JO - Microbes and Infection

JF - Microbes and Infection

SN - 1286-4579

IS - 14-15

ER -